KLP Kapitalforvaltning AS Sells 5,000 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

KLP Kapitalforvaltning AS reduced its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 56.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,800 shares of the medical instruments supplier's stock after selling 5,000 shares during the quarter. KLP Kapitalforvaltning AS's holdings in LeMaitre Vascular were worth $319,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in LeMaitre Vascular by 45.9% during the 4th quarter. JPMorgan Chase & Co. now owns 147,489 shares of the medical instruments supplier's stock valued at $13,590,000 after purchasing an additional 46,430 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in LeMaitre Vascular by 239.5% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 9,833 shares of the medical instruments supplier's stock worth $906,000 after buying an additional 6,937 shares during the period. Alliancebernstein L.P. raised its position in LeMaitre Vascular by 6.0% during the 4th quarter. Alliancebernstein L.P. now owns 22,584 shares of the medical instruments supplier's stock worth $2,081,000 after buying an additional 1,287 shares during the last quarter. Franklin Resources Inc. lifted its stake in LeMaitre Vascular by 8.2% during the 4th quarter. Franklin Resources Inc. now owns 13,678 shares of the medical instruments supplier's stock valued at $1,260,000 after acquiring an additional 1,032 shares during the period. Finally, Geode Capital Management LLC lifted its stake in LeMaitre Vascular by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier's stock valued at $50,711,000 after acquiring an additional 7,737 shares during the period. Institutional investors own 84.64% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Barrington Research reaffirmed a "market perform" rating on shares of LeMaitre Vascular in a research note on Tuesday, July 22nd. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $97.83.

LeMaitre Vascular Stock Down 0.9%

Shares of NASDAQ LMAT opened at $81.24 on Friday. The stock has a market cap of $1.84 billion, a PE ratio of 41.03, a price-to-earnings-growth ratio of 2.16 and a beta of 0.82. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58. The business has a 50-day moving average price of $82.53 and a 200 day moving average price of $87.05. The company has a quick ratio of 13.83, a current ratio of 16.49 and a debt-to-equity ratio of 0.48.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). The business had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a net margin of 19.96% and a return on equity of 13.53%. The firm's quarterly revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.44 earnings per share. Equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 76,868 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $85.79, for a total transaction of $6,594,505.72. Following the transaction, the chief executive officer directly owned 1,796,783 shares of the company's stock, valued at $154,146,013.57. The trade was a 4.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 100,000 shares of company stock worth $8,556,857. Corporate insiders own 9.50% of the company's stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.